Because approved dopamine D2 receptor antagonists (such as metoclopramide) have labels that include AEs associated with hyperprolactinemia (eg, impaired reproductive function), longer‐term administration during the planned phase 2 and 3 studies will be used to monitor for potential adverse events associated with elevated prolactin levels. The gene discussed is DRD2; the disease is hyperprolactinemia.